Complement-mediated Inhibition of Immune Precipitation in Rheumatoid Vasculitis

Overview

Journal Rheumatol Int

Specialty Rheumatology

Date 1990 Jan 1

PMID 2259841

Citations 1

Authors

M M OSullivan

N Amos

A Bedwell

B D Williams

Affiliations

Soon will be listed here.

Abstract

Complement-mediated inhibition of immune precipitation (CMIP) was measured in patients with rheumatoid arthritis (RA), rheumatoid vasculitis (RA VASC), patients with skin vasculitis not associated with a systemic connective tissue disease and normal healthy controls. CMIP was impaired in 100% (14/14) of the RA vasculitic patients, 60% (12/20) of the RA patients and 22% (2/9) of the dermovasculitic patients. The degree of impairment of CMIP was significantly greater in the RA vasculitic patients compared to the non-vasculitic patients. This difference was due to the significantly lower complement levels and the presence of higher concentrations of an inhibitor of CMIP in the RA vasculitic sera. The levels of this inhibitory activity correlated significantly with IgM rheumatoid factor concentration. Serial studies in three patients with RA vasculitis treated with corticosteroids and immunosuppressive drugs showed significant clinical improvement in two patients, which was associated with improvement in CMIP, reduction in circulating immune complex levels and reduction in IgM rheumatoid factor concentrations.

Citing Articles

Endothelial cell damage in rheumatoid disease correlates with complement consumption and immune complexes.

Blann A Rheumatol Int. 1991; 11(2):87.

PMID: 1947674 DOI: 10.1007/BF00291152.

References

Naama J, Mitchell W, Zoma A, Veitch J, Whaley K . Complement-mediated inhibition of immune precipitation in patients with immune complex diseases. Clin Exp Immunol. 1983; 51(2):292-8. PMC: 1536892. View

Schifferli J, Ng Y, Estreicher J, Walport M . The clearance of tetanus toxoid/anti-tetanus toxoid immune complexes from the circulation of humans. Complement- and erythrocyte complement receptor 1-dependent mechanisms. J Immunol. 1988; 140(3):899-904. View

Schifferli J, Ng Y, PETERS D . The role of complement and its receptor in the elimination of immune complexes. N Engl J Med. 1986; 315(8):488-95. DOI: 10.1056/NEJM198608213150805. View

Cornacoff J, Hebert L, Smead W, VanAman M, Birmingham D, Waxman F . Primate erythrocyte-immune complex-clearing mechanism. J Clin Invest. 1983; 71(2):236-47. PMC: 436862. DOI: 10.1172/jci110764. View

Faith A, Pontesilli O, Unger A, Panayi G, Johns P . ELISA assays for IgM and IgG rheumatoid factors. J Immunol Methods. 1982; 55(2):169-77. DOI: 10.1016/0022-1759(82)90029-1. View

Mitchell W, Naama J, Veitch J, Whaley K . IgM-RF prevents complement-mediated inhibition of immune precipitation. Immunology. 1984; 52(3):445-8. PMC: 1454486. View

Mitchell W, Veitch J, Hunter J, Zoma A, Capell H, Whaley K . An inhibitor of complement-mediated prevention of immune precipitation in rheumatoid arthritis--relationship to disease activity and systemic manifestations. Rheumatol Int. 1986; 6(5):209-13. DOI: 10.1007/BF00541369. View

ROSANO C, Braun C, Hechemy K, Parhami N, SATOH P, HURWITZ C . Inhibition of C1q functions by RHP, a protein elevated in sera from patients with rheumatoid arthritis. Complement. 1988; 5(2):57-64. DOI: 10.1159/000463036. View

Schifferli J, Bartolotti S, PETERS D . Inhibition of immune precipitation by complement. Clin Exp Immunol. 1980; 42(2):387-94. PMC: 1537108. View

10.

Conn D, MCDUFFIE F, Dyck P . Immunopathologic study of sural nerves in rheumatoid arthritis. Arthritis Rheum. 1972; 15(2):135-43. DOI: 10.1002/art.1780150202. View

11.

Naama J, Mitchell W, Whaley K . Inhibition of complement-mediated solubilization of antigen-antibody complexes by sera from patients with rheumatoid arthritis. Clin Exp Immunol. 1983; 54(2):429-38. PMC: 1535903. View

12.

Erhardt C, Mumford P, Maini R . The association of cryoglobulinaemia with nodules, vasculitis and fibrosing alveolitis in rheumatoid arthritis and their relationship to serum C1q binding activity and rheumatoid factor. Clin Exp Immunol. 1979; 38(3):405-13. PMC: 1537919. View

13.

Arnett F, Edworthy S, Bloch D, McShane D, Fries J, Cooper N . The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988; 31(3):315-24. DOI: 10.1002/art.1780310302. View

14.

Waxman F, Hebert L, Cosio F, Smead W, VanAman M, Taguiam J . Differential binding of immunoglobulin A and immunoglobulin G1 immune complexes to primate erythrocytes in vivo. Immunoglobulin A immune complexes bind less well to erythrocytes and are preferentially deposited in glomeruli. J Clin Invest. 1986; 77(1):82-9. PMC: 423312. DOI: 10.1172/JCI112306. View

15.

Ahmed A, Whaley K . Purification of a plasma protein that inhibits complement-mediated prevention of immune precipitation. Immunology. 1988; 64(1):45-50. PMC: 1385184. View

16.

BALESTRIERI G, Tincani A, Migliorini P, Ferri C, Cattaneo R, Bombardieri S . Inhibitory effect of IgM rheumatoid factor on immune complex solubilization capacity and inhibition of immune precipitation. Arthritis Rheum. 1984; 27(10):1130-6. DOI: 10.1002/art.1780271008. View

17.

Franco A, Schur P . Hypocomplementemia in rheumatoid arthritis. Arthritis Rheum. 1971; 14(2):231-8. DOI: 10.1002/art.1780140206. View

18.

LAURELL C . Electroimmuno assay. Scand J Clin Lab Invest Suppl. 1972; 124:21-37. DOI: 10.3109/00365517209102748. View

19.

OSullivan M, Amos N, Williams B . Complement mediated inhibition of immune precipitation in rheumatoid arthritis: studies on interaction of heat aggregated IgG with IgM rheumatoid factor. Ann Rheum Dis. 1988; 47(8):675-80. PMC: 1006721. DOI: 10.1136/ard.47.8.675. View

20.

Kerr M, Wilton E, Naama J, Whaley K . Circulating immune complexes associated with decreased complement-mediated inhibition of immune precipitation in sera from patients with bacterial endocarditis. Clin Exp Immunol. 1986; 63(2):359-66. PMC: 1577364. View